A review of potential cardiovascular uses of intravenous glucagon administration

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 442-447

  White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CATECHOLAMINE; DOBUTAMINE; DOPAMINE; GLUCAGON; IMIPRAMINE; ISOPRENALINE; OXPRENOLOL; PROPRANOLOL; SOTALOL; VERAPAMIL;

ANIMAL MODEL; CARDIOVASCULAR EFFECT; CHRONOTROPISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG OVERDOSE; HUMAN; HYPERGLYCEMIA; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NONHUMAN; REVIEW; VOMITING;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; GLUCAGON; HUMANS; OVERDOSE;

EID: 0032768735     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Pollack CV: Utility of glucagon in the emergency department. J Emerg Med 1993;11:195-205.
2. Sener EK, Gabe S, Henry JA: Response to glucagon in imipramine overdose. Toxicol-Clin Toxicol 1995;33:51-53.
3. Sauvadet A, Rohn T, Pecker F, Pavoine C: Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Circ Res 1996;78:102-109.
4. Sauvadet A, Rohn T, Pecker F, Pavoine C: Arachadonic acid drives mini-glucagon action in cardiac cells. J Biological Chem 1997;272:12437-12445.
5. Ross EM: Pharmacodynamics. In, Hardman JG, Limbird LE (eds.): Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996;29-41.
6. Barnett DB: The sympathetic nervous system and myocardial function and regulation in cardiac failure. In, Barnett DB, Pouleur H, Francis GS (eds.): Congestive Cardiac Failure: Pathophysiology and Treatment. New York: Marcel Dekker, 1993;29-48.
7. Muhlhauser I, Koch J, Berger M: Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care 1985;8:39-42.
8. Pontirolli AE, Calderara A, Perfetti MG, Bareggi SR: Pharmacokinetics of intranasal, intramuscular, and intravenous glucagon in healthy subjects and diabetic patients. Eur J Clin Pharmacol 1993;45:555-558.
9. Dobbins RL, Davis SN, Neal DW, Cobelli C, Cherrington AD: Pulsatility does not alter the response to a physiological increment in glucagon in the conscious dog. Am J Physiol 1994;266:E467-E478.
10. Reynolds JEF: Martindale: The Extra Pharmacopeia 31st Edition. Royal Pharmaceutical Society 1996:1710-1711.
11. Manchester JH, Parmley WW, Matloff JM, et al: Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and in dog. Circulation 1970;41:579-588.
12. Love JN, Leasure JA, Mundt DJ, Janz TG: A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. Clin Toxicol 1992;30:399-412.
13. Illingworth RN: Glucagon for beta-blocker poisoning. Practitioner 1979;223:683-685.
14. Kline JA, Tomaszewski CA, Schroder JD, Raymong RM: Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther 1993;267:744-750.
15. White CM, Chow MSS: Is there a future for positive inotropic agents in advanced heart failure? Formulary 1997;32:255-266.
16. Yao LF, MacLeod KM, McNeill JH: Glucagon induced desensitization: correlation between cyclic AMP levels and contractile force. Eur J Pharmacol 1982;79:147-150.
17. Frishman W, Jacob H, Eisenberg E, Ribner H: Clinical pharmacology of the new beta-adrenergic blocking drugs: self poisoning with beta-adrenoceptor blocking agents recognition and management. Am Heart J 1979;98:798-811.
18. Weinstein RS: Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med 1984;13:1123-1131.
19. Peterson CD, Leeder JS, Sterner S: Glucagon therapy for beta-blocker overdose. DICP 1984;18:394-398.
20. Salzberg MR, Gallagher EJ: Propranolol overdose. Ann Emerg Med 1980;9:26-27.
21. Quezado Z, Lippmann M, Wertheimer J: Severe cardiac, respiratory and metabolic complications of massive verapamil overdose. Crit Care Med 1991;19:436-438.
22. Dolan DL: Intravenous calcium before verapamil to prevent hypotension. Ann Emerg Med 1991;20:588-589.
23. Hariman RJ, Mangiardi LM, McAllister RJ, et al: Reversal of cardiovascular effects of verapamil by calcium and sodium: differences between electrophysiological and hemodynamic response. Circulation 1979;59:797-804.
24. Love JN, Sachdeva DK, Bessman ES, Curtis LA, Howell JM: A potential role for glucagon in the treatment of drug induced symptomatic bradycardia. Chest 1998;114:323-326.
25. Lvoff R, Wilken DE: Glucagon in heart failure and in cardiogenic shock: experience with 50 patients. Circulation 1972;45:534-542.
26. Parmley WW, Glick G, Sonnenblick EH: Cardiovascular effects of glucagon in man. N Engl J Med 1968;279:12-17.
27. Timmis GC, Lin R, Ramos RG, Gordon S: Prolonged glucagon infusion in cardiac failure. JAMA 1973;223:293-296.
28. Nord HJ, Fontanes AL, Williams JF: Treatment of congestive heart failure with glucagon. Ann Intern Med 1970;72:649-653.
29. Bower MG, Okude S, Jolley WB, Smith LL, Linda L: Hemodynamic effects of glucagon. Arch Surg 1970;101:411-415.
30. Newman BR, Schultz LK: Epinephrine-resistant anaphylactic shock in a patient taking propranolol hydrochloride. Ann Allergy 1981;47:35-37.
31. Zaloga GP, Delacy W, Holmboe E, et al: Glucagon reversal of hypotension in a case of anaphylactic shock. Ann Intern Med 1986;105:65-66.
32. Perkin RM, Anas NG: Mechanisms and management of anaphylactic shock not responding to traditional therapy. Ann Allergy 1985;54:202-208.
33. Sheffer AL: Anaphylaxis. J Allergy Clin Immunol 1985;75:227-233.
34. White CM: Catecholamines and their blockade in congestive heart failure. Am J Health-Syst Pharm 1998;55:676-682.
35. Cummins RO: Defibrillation. In, Cummins RO (ed.): Textbook of Advanced Cardiac Life Support. Dallas, TX: American Heart Association, 1994;1-22.
36. Weaver WD, Cobb LA, Copass MK, et al: Ventricular fibrillation: a comparative trial using 175J and 320J shocks. N Engl J Med 1982;307:1101-1104.
37. Nieman JT, Adomian GE, Garner D, Rosborough JP: Endocardial and transcutaneous pacing, calcium chloride, and epinephrine in postcountershock asystole and bradyarrhythmias. Crit Care Med 1985;13:699-704.
38. Nieman JT, Hayes KS, Garner D, Jagels G, Rennie CJ: Postcountershock pulseless rhythms: hemodynamic effects of glucagon in a canine model. Crit Care Med 1987;15:554-558.
39. Chernish SM, Maglinte DDT: Glucagon: common untoward reactions - review and recommendations. Radiology 1990;177:145-146.
40. Glucagon for Injection Product Package Insert. Eli Lilly Co, Rev. 1994.
41. Mofenson HC, Caraccio TR, Laudano J: Glucagon for propranolol overdose (letter). JAMA 1986;225:2025.